2552 — Hua Medicine Income Statement
0.000.00%
- HK$2.86bn
- HK$1.94bn
- CNY255.89m
Annual income statement for Hua Medicine, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 17.6 | 76.6 | 256 |
Cost of Revenue | |||||
Gross Profit | — | — | 7.69 | 37.4 | 125 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 389 | 322 | 217 | 280 | 497 |
Operating Profit | -389 | -322 | -200 | -203 | -242 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -393 | -326 | -204 | -211 | -250 |
Provision for Income Taxes | |||||
Net Income After Taxes | -393 | -326 | -204 | -211 | -250 |
Net Income Before Extraordinary Items | |||||
Net Income | -393 | -326 | -204 | -211 | -250 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -393 | -326 | -204 | -211 | -250 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.417 | -0.341 | -0.21 | -0.216 | -0.255 |